TY - JOUR
T1 - Combined Role of Troponin and Natriuretic Peptides Measurements in Patients With Covid-19 (from the Cardio-COVID-Italy Multicenter Study)
AU - Iorio, Annamaria
AU - Lombardi, Carlo Mario
AU - Specchia, Claudia
AU - Merlo, Marco
AU - Nuzzi, Vincenzo
AU - Ferraro, Ilenia
AU - Peveri, Giulia
AU - Oriecuia, Chiara
AU - Pozzi, Andrea
AU - Inciardi, Riccardo M.
AU - Carubelli, Valentina
AU - Bellasi, Antonio
AU - Canale, Claudia
AU - Camporotondo, Rita
AU - Catagnano, Francesco
AU - Vecchia, Laura Dalla
AU - Giovinazzo, Stefano
AU - Maccagni, Gloria
AU - Mapelli, Massimo
AU - Margonato, Davide
AU - Monzo, Luca
AU - Provenzale, Giovanni
AU - Sarullo, Filippo
AU - Tomasoni, Daniela
AU - Ameri, Pietro
AU - Gnecchi, Massimiliano
AU - Leonardi, Sergio
AU - Agostoni, Piergiuseppe
AU - Carugo, Stefano
AU - Danzi, Gian Battista
AU - Guazzi, Marco
AU - La Rovere, Maria Teresa
AU - Mortara, Andrea
AU - Piepoli, Massimo
AU - Porto, Italo
AU - Volterrani, Maurizio
AU - Sinagra, Gianfranco
AU - Senni, Michele
AU - Metra, Marco
N1 - Funding Information:
Prof Piergiuseppe Agostoni reported nonfinancial support from Menarini, Novartis, and Boehringer; grants from Daiichiò Sankyo and Bayer; and grants and nonfinancial support from Actelion outside the submitted work. Prov Pietro Ameri reported having received speaker and advisor honoraria from Novartis, AstraZeneca, Vifor, Daiichi Sankyo, Boehringer Ingelheim, Pfizer, GlaxoSmithKline, and Merck, Sharp & Dohme and nonfinancial support from Actelion outside the submitted work. Dr Valentina Carubelli received consulting honoraria from CVie Therapeutics Limited, Servier, and Windtree Therapeutics outside the submitted work. Dr. Riccardo Maria Inciardi received speaker and advisor honoraria from Daiichi-Sankyo, Boehringer Ingelheim. Prof Sergio Leonardi reported grants and personal fees from AstraZeneca and personal fees from BMS/Pfizer, Novo Nordisk, and Chiesi outside the submitted work. Prof Carlo Mario Lombardi received speaker and advisor honoraria from Novartis and Astra Zeneca. Dr Andrea Mortara reports personal consulting honoraria from Novartis, Servier, Astra Zeneca for participation to advisory board meetings and receives grants from Novartis and Niccomo for research trials. Prof Massimo Piepoli reported having received research grants and speaking fees from Novartis, Servier, and TRX and nonfinancial support from Vifor outside the submitted work. Prof Michele Senni reported personal fees from Novartis, Abbott, Merck, Bayer, Boehringer, Vifor, and AstraZeneca outside the submitted work. Prof Marco Metra reported personal consulting honoraria from Abbott Vascular, Amgen, Bayer, Edwards Therapeutics, Servier, Vifor Pharma, and Windtree Therapeutics for participation to advisory board meetings and executive committees of clinical trials. All other authors have nothing to disclose.
Publisher Copyright:
© 2021 Elsevier Inc.
PY - 2022
Y1 - 2022
N2 - Data concerning the combined prognostic role of natriuretic peptide (NP) and troponin in patients with COVID-19 are lacking. The aim of the study is to evaluate the combined prognostic value of NPs and troponin in hospitalized COVID-19 patients. From March 1, 2020 to April 9, 2020, consecutive patients with COVID-19 and available data on cardiac biomarkers at admission were recruited. Patients admitted for acute coronary syndrome were excluded. Troponin levels were defined as elevated when greater than the 99th percentile of normal values. NPs were considered elevated if above the limit for ruling in acute heart failure (HF). A total of 341 patients were included in this study, mean age 68 ± 13 years, 72% were men. During a median follow-up period of 14 days, 81 patients (24%) died. In the Cox regression analysis, patients with elevated both NPs and troponin levels had higher risk of death compared with those with normal levels of both (hazard ratio 2.94; 95% confidence interval 1.31 to 6.64; p = 0.009), and this remained significant after adjustment for age, gender, oxygen saturation, HF history, and chronic kidney disease. Interestingly, NPs provided risk stratification also in patients with normal troponin values (hazard ratio 2.86; 95% confidence interval 1.21 to 6.72; p = 0.016 with high NPs levels). These data show the combined prognostic role of troponin and NPs in COVID-19 patients. NPs value may be helpful in identifying patients with a worse prognosis among those with normal troponin values. Further, NPs’ cut-point used for diagnosis of acute HF has a predictive role in patients with COVID-19.
AB - Data concerning the combined prognostic role of natriuretic peptide (NP) and troponin in patients with COVID-19 are lacking. The aim of the study is to evaluate the combined prognostic value of NPs and troponin in hospitalized COVID-19 patients. From March 1, 2020 to April 9, 2020, consecutive patients with COVID-19 and available data on cardiac biomarkers at admission were recruited. Patients admitted for acute coronary syndrome were excluded. Troponin levels were defined as elevated when greater than the 99th percentile of normal values. NPs were considered elevated if above the limit for ruling in acute heart failure (HF). A total of 341 patients were included in this study, mean age 68 ± 13 years, 72% were men. During a median follow-up period of 14 days, 81 patients (24%) died. In the Cox regression analysis, patients with elevated both NPs and troponin levels had higher risk of death compared with those with normal levels of both (hazard ratio 2.94; 95% confidence interval 1.31 to 6.64; p = 0.009), and this remained significant after adjustment for age, gender, oxygen saturation, HF history, and chronic kidney disease. Interestingly, NPs provided risk stratification also in patients with normal troponin values (hazard ratio 2.86; 95% confidence interval 1.21 to 6.72; p = 0.016 with high NPs levels). These data show the combined prognostic role of troponin and NPs in COVID-19 patients. NPs value may be helpful in identifying patients with a worse prognosis among those with normal troponin values. Further, NPs’ cut-point used for diagnosis of acute HF has a predictive role in patients with COVID-19.
UR - http://www.scopus.com/inward/record.url?scp=85122976941&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85122976941&partnerID=8YFLogxK
U2 - 10.1016/j.amjcard.2021.11.054
DO - 10.1016/j.amjcard.2021.11.054
M3 - Article
AN - SCOPUS:85122976941
SN - 0002-9149
JO - American Journal of Cardiology
JF - American Journal of Cardiology
ER -